Summary

Linagliptin is an oral hypoglycemic compound used in the treatment of T2DM. The target of the drug is dipeptidyl peptidase 4, an enzyme that is important in various functions including the metabolism of glucose. This article discusses the cardiovascular (CV) safety of linagliptin in nearly 9500 patients with type 2 diabetes mellitus with a wide spectrum of CV risk and treatment history, based on an analysis of 19 randomized controlled trials.